NASDAQ:BOLD Boundless Bio (BOLD) Stock Price, News & Analysis $2.83 +0.05 (+1.80%) Closing price 04:00 PM EasternExtended Trading$2.73 -0.10 (-3.50%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About Boundless Bio Stock (NASDAQ:BOLD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boundless Bio alerts:Sign Up Key Stats Today's Range$2.74▼$2.8450-Day Range$1.38▼$2.8952-Week Range$0.96▼$2.97Volume108,951 shsAverage Volume264,691 shsMarket Capitalization$64.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. Read More Boundless Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreBOLD MarketRank™: Boundless Bio scored higher than 36% of companies evaluated by MarketBeat, and ranked 719th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingSell Consensus RatingBoundless Bio has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 2 sell ratings.Amount of Analyst CoverageBoundless Bio has only been the subject of 2 research reports in the past 90 days.Read more about Boundless Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Boundless Bio is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Boundless Bio is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBoundless Bio has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.30% of the float of Boundless Bio has been sold short.Short Interest Ratio / Days to CoverBoundless Bio has a short interest ratio ("days to cover") of 1.52, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Boundless Bio has recently decreased by 6.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoundless Bio does not currently pay a dividend.Dividend GrowthBoundless Bio does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentBoundless Bio has a news sentiment score of 1.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Boundless Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BOLD on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $565,005.00 in company stock, which represents 0.8776% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Boundless Bio insiders have bought 709.09% more of their company's stock than they have sold. Specifically, they have bought $644,685.00 in company stock and sold $79,680.00 in company stock.Percentage Held by Insiders23.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBoundless Bio has minimal institutional ownership at this time.Read more about Boundless Bio's insider trading history. Receive BOLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boundless Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLD Stock News HeadlinesHalper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their ShareholdersJuly 2, 2026 | globenewswire.comBoundless Bio to merge with Serapha Bio in reverse merger; shares surgeJune 23, 2026 | msn.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.August 14 at 1:00 AM | Profits Run (Ad)BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company HistoryJune 23, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)June 23, 2026 | prnewswire.comBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementJune 23, 2026 | globenewswire.comBoundless Bio Reports First Quarter 2026 Financial Results and Business HighlightsMay 8, 2026 | globenewswire.comBoundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingApril 17, 2026 | globenewswire.comSee More Headlines BOLD Stock Analysis - Frequently Asked Questions How have BOLD shares performed this year? Boundless Bio's stock was trading at $1.18 at the start of the year. Since then, BOLD shares have increased by 139.8% and is now trading at $2.83. How were Boundless Bio's earnings last quarter? Boundless Bio, Inc. (NASDAQ:BOLD) posted its earnings results on Friday, August, 7th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter. When did Boundless Bio IPO? Boundless Bio (BOLD) raised $100 million in an initial public offering (IPO) on Thursday, March 28th 2024. The company issued 6,250,000 shares at $15.00-$17.00 per share. Who are Boundless Bio's major shareholders? Top institutional investors of Boundless Bio include ADAR1 Capital Management LLC (8.65%), BlackRock Inc. (0.39%) and GSA Capital Partners LLP (0.32%). Insiders that own company stock include Ra Capital Management, LP and Venture Fund Ix LP Arch. View institutional ownership trends. How do I buy shares of Boundless Bio? Shares of BOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boundless Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boundless Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG) and Visa (V). Company Calendar Last Earnings8/07/2026Today8/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 BOLD's financial health is in the Green zone, according to TradeSmith. BOLD has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLD CIK0001782303 Webwww.boundlessbio.com Phone(858) 766-9912FaxN/AEmployees64Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-70.89% Return on Assets-47.37% Debt Debt-to-Equity RatioN/A Current Ratio9.48 Quick Ratio9.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book0.98Miscellaneous Outstanding Shares22,750,000Free Float17,493,000Market Cap$64.38 million OptionableNo Data Beta-0.08 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:BOLD) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredAI insiders stockpile guns, gold & gas masksKeith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...TradeSmith | SponsoredWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWho Really Gets Rich from IPOs?Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...Weiss Ratings | Sponsored$100 for this… $500 for that. Here’s how to stop the bleeding todayRising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boundless Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Boundless Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLD Stock Alerts